Monopar Therapeutics Inc. — Q3 2019 Form 10-Q
Reporting period: Three and nine months ended September 30, 2019; filed November 12, 2019. Monopar is a clinical-stage biopharmaceutical company developing oncology therapies and reported no product revenue.
Financial performance and position
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $220,000 | $304,000 | $1.385 million | $1.253 million |
| General and administrative expense | $540,000 | $364,000 | $1.714 million | $1.151 million |
| Total operating expenses | $759,000 | $668,000 | $3.099 million | $2.405 million |
| Net loss | $736,000 | $640,000 | $3.018 million | $2.337 million |
| Net loss per share, basic and diluted | $0.08 | $0.07 | $0.32 | $0.25 |
| Operating cash used | — | $2.349 million | $2.161 million |
At September 30, cash and cash equivalents were $4.495 million, versus $6.893 million at December 31, 2018. Current assets were $5.109 million and current liabilities $484,000; the company reported no debt. Stockholders’ equity was $4.625 million and accumulated deficit $24.674 million. No profit margin is meaningful because the company had no revenue and incurred losses.
Changes from comparable periods
- Q3 net loss increased about 15% year over year; nine-month net loss increased about 29%.
- Nine-month operating expenses rose $694,000. R&D increased $132,000, while G&A rose $563,000, largely reflecting higher stock-based compensation, audit costs, board fees and salaries.
- Q3 R&D expense declined $84,000, primarily because of a reduction in a prior Validive manufacturing accrual, partly offset by increased consulting and stock compensation.
- Nine-month operating cash use increased $188,000 year over year. Cash declined $2.398 million during the first nine months of 2019.
Outlook, development plans and risks
- Management estimated that available funds as of November 12, 2019 would cover minimum or “minimal” required operations through December 2020. This estimate is assumption-dependent; management expected to seek additional capital through equity, debt, collaborations or grants.
- Monopar aimed to begin a Phase 3 Validive program in Q1 2020, following FDA and EMA feedback on the protocol and statistical analysis plan. The proposed program included an adaptive trial and a planned confirmatory trial. Validive has U.S. fast-track and EU orphan designations.
- A GEIS-led, randomized Phase 2 trial of camsirubicin versus doxorubicin in about 170 patients with advanced soft-tissue sarcoma was expected to begin enrolling in Q1 2020. Monopar expected to provide drug and supplemental support averaging approximately $1–2 million annually. In October 2019, the EMA committee adopted a positive opinion on EU orphan designation for camsirubicin.
- MNPR-101 was at the pre-IND stage; the company said IND-enabling work was nearly complete.
- Management expected expenses to increase from Q1 2020 due to planned clinical trials, manufacturing and process-development work, staffing and consulting. Funding shortfalls, trial delays or costs, regulatory outcomes, competition and the need for further financing could delay, reduce or terminate development. Additional equity financing could dilute shareholders.
- Potential contractual payments include Validive milestones of up to $108 million plus 5%–10% royalties on net sales, and MNPR-101 milestones of up to $14.925 million; no milestones had been reached as of the filing. No material legal proceedings were reported. The filing stated there were no material changes to previously disclosed risk factors.
Key investor verification points
- Verify cash runway against actual spending and the scope of “minimal operations”; the runway estimate did not imply funding the full planned development programs.
- Track whether Validive Phase 3 and the GEIS camsirubicin trial began on schedule, their funding needs, and subsequent regulatory or clinical updates.
- Review financing activity and potential dilution, including the $529,000 in deferred offering costs reported at September 30.
- Assess related-party governance and ownership disclosures: the filing reported Tactic Pharma beneficial ownership of 46% and TacticGem ownership of 77% of common stock, and disclosed payments to executives and directors with related affiliations.
- Consider equity compensation overhang: 1,105,896 options were outstanding, compared with 9,291,421 common shares outstanding; options were excluded from diluted loss per share as anti-dilutive.